Gilead Sciences (NASDAQ:GILD) First Quarter 2025 Results

Key Financial Results

• Revenue: US$6.67b (flat on 1Q 2024).
• Net income: US$1.32b (up from US$4.17b loss in 1Q 2024).
• Profit margin: 20% (up from net loss in 1Q 2024).
• EPS: US$1.06 (up from US$3.34 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in Gilead Sciences. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Gilead Sciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 1.3% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Gilead Sciences.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.